A carregar...
Publicação
Aspirin for primary cardiovascular prevention in patients with family history of cardiovascular disease : meta-analysis
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 397.58 KB | Adobe PDF |
Orientador(es)
Resumo(s)
The use of aspirin, while well established in the secondary prevention of cardiovascular events, remains controversial in the primary prevention of these events in the general adult population. In this setting, aspirin showed a significant but modest decrease of cardiovascular event incidence at the cost of a significantly increased risk of bleeding, a pattern that is also seen in higher risk patients, such as diabetics. It becomes exceedingly important to identify other patient clusters that would benefit from cardiovascular risk reduction at the best benefit/risk ratio.
Descrição
© 2020 Springer Nature Switzerland AG. Part of Springer Nature.
Palavras-chave
Contexto Educativo
Citação
Cardiovasc Drugs Ther (2020).
Editora
Springer Nature